mAb developer Oncobiologics launches CDMO business

By Melissa Fassbender contact

- Last updated on GMT

mAb developer Oncobiologics launches CDMO business
Oncobiologics has launched a CDMO business to provide mAb development and manufacturing capabilities in a small biotech company setting, says CFO.

Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing, and commercializing monoclonal antibody (mAb) therapeutics.

The company’s contract development and manufacturing (CDMO) business is based on its BioSymphony Platform, which also is used for in-house programs, and combines its capabilities with the India-headquartered firm Stelis Biopharma Private Limited​ to provide mammalian and microbial cell process development and bulk drug manufacturing.

The CDMO business also offers fill-finish services, including drug formulation development and lyophilization for biological products.

“Oncobiologics developed its CDMO platform to provide affordable, clinically important therapies,”​ said Larry Kenyon, Oncobiologics CFO.

“This platform enables the company to leverage its in-house mAb development and manufacturing capabilities in a small biotech company setting, resulting in a more efficient and timely process for bringing mAbs forward,”​ he told us.

In tandem with the CDMO launch, Oncobioglocis also has announced that is has entered into a Master Services Agreement (MSA) with Sonnet BioTherapeutics, a privately held development stage biopharmaceutical company.

Under the agreement – specific terms of which were not disclosed – Oncobiologics will provide its CDMO services for up to four drug product candidates over the next three years.

Pankaj Mohan, PhD, chairman and CEO of Oncobiologics said in a press release: “We believe this CDMO business, and the associated revenue, integrated with our ongoing efforts to develop our own proprietary innovative and biosimilar product candidates, will help us to reduce costs and improve efficiency to drive stockholder value."

Related news

Show more

Related products

show more

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us

Products

View more

Webinars